Health and Environment – Pharmaceuticals development

Fraunhofer scientists research pharmaceutical agents for the treatment of diseases such as cancer, allergies, inflammatory and autoimmune conditions, and infections. For the production of pharmaceutical agents used in preclinical and clinical trials, we have at our disposal the most state-of-the-art equipment meeting the specifications of the European Medicines Agency EMEA and the American Food and Drug Administration FDA. Pharmaceutical agents and manufacturing processes are developed in accordance with the rules of the Good Manufacturing Process (GMP).

Gesundheit und Umwelt

Projects

New agents to fight multidrug-resistant germs

Research News / 2.1.2020

Resistance to antibiotics is on the rise worldwide. Fraunhofer scientists have joined forces with partners in the Phage4Cure project to explore alternatives to antibiotics. One objective is to vanquish multidrug-resistant pathogens with viruses called bacteriophages. Another is to see these phages approved to treat the dreaded hospital germ Pseudomonas aeruginosa, the most frequent bacterial cause of pneumonia.

more info

Making novel therapeutics safer: Interdisciplinary EU consortium develops innovative model systems for the evaluation of immunomodulating therapeutics

Press Release Fraunhofer IZI 3.12.2019

The development of immunomodulatory agents and therapies has received fresh impetus following the latest successes in immuno-oncology. And cancer medicine is not the only area where cell and gene therapies are increasingly taking hold as alternatives or complementary to classic, low-molecular drugs and biologicals.

more info

Early diagnosis and individualized treatment of immune diseases

Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD

The primary goal of the Fraunhofer Cluster of Excellence for Immune-Mediated Diseases is the translation of innovative ideas and identified targets into individualized therapies for immune-mediated diseases. In the medium term, the collaborating institutes want to bridge the existing gap from research on novel medications to what is actually available to patients.

Platform for the Identification of ncRNA-Based Diagnostics – RIBOLUTION

In molecular diagnostics the presence or concentration of specific molecules, so-called biomarkers, is used as indicators of disease or the response to a particular form of therapy. Improved early detection therefore enables difficult and costly disease progressions to be avoided.

more info

Translational medicine and pharmacology

Work undertaken by the Translational Medicine and Pharmacology project group at the Fraunhofer Institute for Molecular Biology and Applied Ecology IME is concerned with finding new drug ingredients, developing preclinical and clinical models, and clinical research.

The German Center for Lung Research

The German Center for Lung Research (DZL) is an association of the leading university and non-university institutions dedicated to lung research in Germany and including Fraunhofer ITEM.  Using translational research methods, the DZL seeks to jointly develop new approaches for the prevention, diagnosis and therapy of serious lung diseases.

more info

Clinical Research Center Hannover

The three partners to the CRC Hannover – Fraunhofer ITEM, MHH, and HZI – will be using the center collaboratively to conduct early-phase clinical trials for the development and registration of novel medications and to do patient-oriented research.